Background: Many medications used to manage multiple sclerosis (MS) affect oral health. This review aimed to identify the oral side-effects of the current drugs recommended in Australia to treat MS and make dental practitioners aware of the range of symptoms. Methods: The Australian Therapeutic Guidelines and the Australian Medicines Handbook were searched for medications used to treat MS. For each medication, the generic name, class, route of administration, dosage and drug company reported side-effects were extracted from the online Monthly Index of Medical Specialties (MIMs) database. Meyler's Side-effect of Drugs Encyclopaedia was used to identify any additional oral adverse reactions to medications used to treat MS. Results: Fourteen drugs were identified for the treatment of MS progression and 13 drugs for the treatment of MS symptoms. For these medications, 18 oral side-effects were documented: xerostomia was the most common, followed by dysgeusia, dysphagia, mouth ulceration and sinusitis. Anticholinergic drugs caused xerostomia while immunosuppressants resulted in more infection-related side-effects. Conclusions: Dental practitioners should be aware of the range of symptoms likely to be reported by this population. Clinicians are encouraged to continue providing dental care for their patients who develop MS and refer complex cases to specialists.
INTRODUCTION
Multiple sclerosis (MS) is an autoimmune disease with unknown aetiology that results in the loss of the myelin-oligodendrocyte complex in the central nervous system (CNS). [1] [2] [3] In Australia, it is estimated that at least 23 700 people (0.1% of the population) live with MS, and global rates are increasing yearly. 4, 5 There are four types of MS, classified by the severity of the symptoms experienced: (i) benign; (ii) relapseremitting; (iii) primary progressive; or (iv) secondary progressive. 2 People living with MS may experience periods of remissions and relapses of their symptoms. 6 Progression of the disease results in a decrease in remissions of symptoms. 6 MS has a variety of physical and cognitive symptoms and individuals experience varying combinations of symptoms. 6 Common symptoms include extreme fatigue, sensory disturbance, visual disturbance, problems with mobility and balance, muscle weakness, spasticity, ataxia, bladder, bowel and sexual dysfunction, pain and trigeminal neuralgia, dysarthria, dysphagia, vertigo and respiratory dysfunction. 3, 6 Orofacial manifestations of MS may occur due to demyelination of nerves in the head and neck. 7 Symptoms resulting from this include trigeminal neuralgia and other patterns of pain, numbness, muscle weakness, tremor, hemifacial spasms, dysphagia and involuntary facial muscle contractions. 7 Multiple sclerosis is managed by pharmacological and non-pharmacological strategies with the aim of preventing relapse of symptoms and progression of the disease. 8, 9 Due to the complexity of the disease and variability of symptoms, multidisciplinary management is required, and may involve primary care physicians, neurologists, nurses, physical therapists, psychologists, occupational therapists and other allied health professionals. 8, 9 The non-pharmacological management of MS includes therapies aimed at the management of physical symptoms. 8, 9 Currently, no 
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The official journal of the Australian Dental Association cure exists for MS and medications are used to slow disease progression and also to manage the symptoms of MS. 8, 9 Medications used internationally differ due to varying guidelines and approved drugs in each country. 10 In Australia, guidelines for the treatment of MS are published in the Australian Therapeutic Guidelines and the Australian Medicines Handbook. 11, 12 Broad-spectrum immunosuppressants and immunomodulators are used to manage disease progression, whereas symptoms are managed using a variety of drugs, including anticholinergics. 12 The drugs taken to slow the progression of MS and manage its associated symptoms may have oral sideeffects. Immunosuppressive and immunomodulating therapies increase susceptibility to gingival inflammation and overgrowth, Candida infections, human papillomavirus infection and leukoplakia. [13] [14] [15] [16] Anticholinergic drugs are likely to cause salivary gland hypofunction. 17 Currently, the nature and extent of oral health problems caused by MS, the indirect effects from physical and cognitive symptoms and the effects of medications for people living with MS is relatively unclear. This paper aimed to review the drugs used to treat MS currently recommended by Australian guidelines and to identify the associated oral side-effects.
METHODS
The Australian Therapeutic Guidelines and the Australian Medicines Handbook were searched for drugs used to treat MS and its symptoms. 11, 12 The drugs identified from these sources are listed in Figs. 1 and 2. Both resources are evidence-based guidelines and were written principally to assist prescribing in contemporary Australian practise. 18, 19 The Monthly Index of Medical Specialties (MIMS) electronic database 20 was searched for the drugs described in Figs. 1 and 2 . Each drug and its sideeffects were identified. As defined by MIMS, very common (≥5%), common (≥1%) and uncommon (<1%) oral side-effects were identified. 20 The MIMS resource describes drug side-effects as reported by drug company sponsors. Meyler's Side-effects of Drugs Encylopedia was used to identify additional oral health adverse effects reported in primary and secondary literature.
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RESULTS
Twenty-seven drugs used in the treatment of MS were identified from the Australian Medicines Handbook and The Australian Therapeutic Guidelines (Figs. 1 and 2). 11, 12 Of these, 14 drugs were used to treat MS progression ( Fig. 1 ) and 13 drugs were used to treat the symptoms of MS (Fig. 2) .
Of the 14 drugs identified for treatment of MS progression, 10 were classed as immunomodifiers according to MIMS (Table 1 ). Of the 13 drugs found to treat symptoms of MS, four were classed by MIMS as bladder function disorder drugs, two were muscle relaxants, two as anticonvulsants, two as antidepressants, one anti-anxiety agent, one movement disorder drug and one antispasmodic drug ( Table 2) .
Oral Side-effects of Drugs
The most frequently listed side-effects of drugs used to prevent MS progression were sinusitis and dysgeusia (Table 1) . Almost all of the drugs used for MS symptom management caused xerostomia (Table 2) . Dysphagia and dysgeusia were the next most common side-effects, with four drugs reporting these outcomes (Table 2) .
Overall, there were 18 various oral effects identified. These comprised burning tongue, caries, tongue discolouration, xerostomia, dysgeusia, dysphagia, erythema multiforme, gingivitis, gum haemorrhage, glossitis, hypersalivation, mouth and tongue ulceration, mucositis, oral herpes, oropharyngeal pain, sinusitis and dental pain (Table 1 and 2). Thirteen drugs listed dry mouth as the most common oral side-effect followed by dysgeusia, dysphagia, mouth ulceration and sinusitis. 
DISCUSSION
The medications recommended for management of MS in Australia have a range of effects on the oral cavity. A difference was observed between the oral side-effects of the drugs for MS disease progression and drugs used for the management of symptoms. The medications used to treat MS progression (primarily immunomodifiers) commonly listed toothache and inflammation in the form of sinusitis and mucositis as side-effects. Comparatively, the drugs used to manage MS symptoms most frequently listed xerostomia as a common side-effect.
There is great variability in the expression of MS symptoms and each individual has their own experience of the disease. 22 Furthermore, there may be great variability in the pharmacological and nonpharmacological treatment among people with MS. A thorough discussion and recording of MS symptom experiences, medications used and potential experiences of oral side-effects by dental clinicians is essential in the clinical management of a patient with MS. This information is necessary to establish a patient's risk status for oral diseases and to inform the delivery of tailored preventive oral health care. It is important to individually assess the potential Defined by eMIMS: occurring ≥10% (very common), ≥1% (common) and <1% (uncommon) higher rate than placebo.
impact of physical and cognitive MS symptoms that may directly and indirectly affect personal oral hygiene behaviours and access to professional care. 23 Dental practitioners should be aware of the symptoms people with MS may experience so they can tailor advice and accommodate for their needs during treatment. 23 Toothache, sinusitis and pain problems were sideeffects found in this review of MS drugs. In addition to drug side-effects, common orofacial pain symptoms caused by MS include trigeminal neuralgias and atypical facial pain. [24] [25] [26] A recent focus group study of people with MS found that those experiencing confusing facial pain symptoms reported being dismissed by dental professionals when a dental/tooth problem was unable to be found or diagnosed. 23 Atypical facial pain can present as a toothache or unclear and confusing orofacial pain. [27] [28] [29] In cases where no dental pathology can be identified, misdiagnosis can result in multiple failed treatments and tooth extractions. 30 When treating a patient with MS who reports orofacial pain and no obvious dental problem is noted clinically or radiographically, the patient should be referred to a specialist in special needs dentistry or oral medicine for multidisciplinary care. 31, 32 In Australia, specialists in special needs dentistry or oral medicine manage cases of atypical facial pain, which may present in people with MS. [33] [34] [35] In conjunction with the patient's treating GP or neurologist a diagnosis of trigeminal neuralgia is possible, and the condition may be treated with carbamazepine. 7, 30, 36 General dentists should be aware of the range of symptoms likely to be reported by people with MS and are encouraged to continue providing general dental care for these patients and referring when complex cases arise.
Xerostomia was a very common oral side-effect of taking drugs to manage MS symptoms. Medications that cause a reduction in saliva increase the risk of oral diseases, such as dental caries, periodontal diseases and oral fungal infections. 37, 38 There are various strategies to manage xerostomia, including the stimulation of saliva and saliva substitutes. 17 The management of xerostomia should be a priority for people living with MS, and this includes office application of fluorides and the use of high-strength fluoride toothpastes at home to address the heightened caries risk. Dry mouth gels and rinses may additionally be recommended for symptomatic relief. Defined by eMIMS: occurring ≥10% (very common), ≥1% (common) and <1% (uncommon) higher rate than placebo. ‡ Paroxysmal symptoms of multiple sclerosis include trigeminal neuralgia and paresthesias.
Xerostomia can also make swallowing foods difficult and diets are sometimes altered to assist with swallowing.
17 Dysphagia (difficulty swallowing) and dysgeusia (taste alterations) were common side-effects of medications used to manage MS symptoms. A systematic review found that at least 36% of people with MS have dysphagia or difficulty swallowing. 39 The results of this study suggest that MS medications in addition to the disease itself may contribute to these symptoms. Patients with dysphagia require a multidisciplinary approach (including speech pathologist, clinical dietician, nurse, dentist, carer) to manage swallowing function and reduce the risk of aspiration. 40 There is a paucity of literature describing the implications of dysgeusia among people with MS; however, the literature describing taste alterations in other population groups, such as the elderly and cancer patients, note that dysgeusia is associated with food aversion, diet alterations and nutritional compromise. [41] [42] [43] [44] Food intake has been identified as an important risk factor for malnutrition in people with MS. 45, 46 Further studies investigating the influence of oral health on dietary intake are needed.
CONCLUSIONS
A range of oral symptoms from anticholinergic and immunosuppressants drugs are likely to be reported by people with MS. Xerostomia and oral infections were frequently reported oral side-effects, but symptoms and the medications taken by people with MS differ within individuals. Clinicians should be aware of the range of symptoms likely to be reported by this population and the importance of recording an accurate medical history. Dental practitioners are encouraged to continue providing dental care for their patients who develop MS and refer complex cases of atypical facial pain and trigeminal neuralgia to specialists in special needs dentistry or oral medicine.
